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ABSTRACT
Relapsing polychondritis (RP) is a rare immune-mediated disease that occurs with recurrent inflammatory 
processes in cartilage structures and tissues rich in proteoglycans throughout the body, in particular the 
ears, nose, eyes, and joints. The long time between relapses makes diagnosis difficult and often the disease 
remains unrecognized. We present a case of a 56-year-old patient diagnosed with RP. The diagnosis is 
based on clinical indicators: polyarthritis, chondritis on ear cartilage, and good response to corticosteroid 
treatment.
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INTRODUCTION 
Relapsing polychondritis (RP) is a rare im-
mune-mediated condition that occurs with recurrent 
inflammatory processes in cartilage structures and 
tissues rich in proteoglycans throughout the body, 
in particular the ears, nose, eyes, joints and airways 
(Orpha code: 728). The process leads to anatomical 
deformations and disturbances in the normal func-
tioning of the affected structures. The unclear etiol-
ogy and pathogenesis, as well as the fact that the dis-
ease is extremely rare, complicate both diagnosis and 
therapy.
PRESENTATION
We present a 56-year-old female patient who 
was hospitalized for erysipelas-like inflammation of 
both ears in 2019. On admission, the patient com-
plained of nighttime shortness of breath and feeling 
of oppression in the larynx area. She also reported 
hearing problems and headache. From her medical 
history: in 2012, the left knee joint was replaced, and 
in 2018, the right hip joint was replaced. The derma-
tological status showed well-defined edema and er-
ythema bilaterally in the area of the ear cartilage. 
Desquamation and palpation tenderness were ob-
served. From the performed research, laryngoscopy 
was established as normal. The Ro graph of the lung 
was normal. No deviation was observed in the blood 
count incl. RF, except for ESR and CRP, which were 
slightly elevated. Biopsy of the right auricle revealed 
a chaotic arrangement and fragmentation of collagen 
fibers, and loosening of the stroma. The antibiotic 
treatment was without response. The improvement 
of symptoms started after corticosteroid treatment, 
which started with an initial dose of 50 mg/day, fol-
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Based on found deviations in autoantibodies 
against collagen II, IX, XI, matrilin-1 and COMP 
(cartilage oligomeric matrix complex) as well as con-
sidering the role of cell-mediated immunity (IL2, 
IL12, matrix metalloproteinase (MMP) -3, 8, 9 and 
cathepsins K, L),the most likely hypothesis for the 
pathogenesis of the disease is that unknown factors 
(infection, mechanical or chemical aggressor) pro-
voke protein degranulation and lead to release of spe-
cific antigens against cartilage structures (8-10).
The clinicаl presentation is dominated by chon-
drites of the auricle - 90% (11), nasal cartilage 54% 
(12), and laryngotracheobronchial - 10% (13) involve-
ment. The second most common symptom of the 
disease is arthropathy (11). Eye changes, nervous sys-
tem symptoms, renal changes, and various skin con-
ditions and lesions are relatively common (14,15).
There have been a number of reports of the as-
sociation of RP with other diseases. The most often 
mentioned are: autoimmune diseases, rheumatolog-
ic diseases, vasculitis, myelodysplastic syndrome, tu-
mors (bladder, breast, lung, and pancreas), and lym-
phomas (16).
The diagnosis is challenging due to the lack of 
specific clinical, histological and laboratory findings 
(17). The first diagnostic criteria were offered by Mc-
Adam on the basis of the observation of 159 patients. 
Later, Damiani and Leveni, as well as Michet and as-
sociates, modified these criteria (18).
The unclear etiology and pathogenesis, as well 
as the fact that the disease is extremely rare, com-
plicate not just the diagnosis but the therapy as well. 
There are single and unsystematic reports in the lit-
erature on the use of various drugs with variable ef-
fect. Studies on the benefits of corticosteroid treat-
ment are still numerous, but these drugs do not pre-
vent recurrences and subsequent complications 
of RP. Therapy also could be performed with dap-
sone or colchicine. Individual patients show good re-
sponse when administered biologics. The biologic 
agents used to treat RP include tumor necrosis factor 
inhibitors, rituximab, anakinra, tocilizumab, abata-
cept, and others.
The Relapsing Polychondritis Disease Activity 
Index (RPDAI) is relatively new score, which is de-
signed to evaluate disease activity in a standardized 
manner. It consists of 27 individual assessment ques-
lowed by reduction by 10 mg weekly until achieving 
a dose of 4-8 mg/day.
DISCUSSION
RP is a multisystem autoimmune disease with a 
diverse clinical picture and without clear diagnostic 
and therapeutic criteria. Its relatively late recognition 
is a major cause of complications and deformities of 
the affected cartilage structures
In 1923, Rudolf Jaksch von Waetenhorst first 
described the disease and named it polychondro-
pathia (1). Later, patients with similar symptoms 
were described by other authors under different 
names until 1960, when Pearson and coauthors in-
troduced the current name emphasizing the recur-
rent nature of the disease (2).
Annual incidence varies from 0.71 to 3.5 per 
million according to different authors (3). Most of-
ten, the first manifestation is between 40 and 60 
years of age, although RP may also occur in child-
hood. Pediatric RP cases represent up to 5% of all pa-
tients. The age range is between 1.7 months and 17 
years (4). Pregnancy is not affected by the disease (5). 
No neonatal cases have been described. Epidemio-
logical researches reveal a slight prevalence of female 
patients.
The etiology is unknown. A link between RP 
and HLA class II, in particular HLA-DR4, has been 
described (6). In the literature, cases of RP after drug 
or toxin incidents have been revealed (7).
Fig. 1. Image of the left ear of the patient
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tions, each ranging from 1 to 24. Theoretically, the 
maximum RPDAI is 265, reporting over a period of 
28 days (19).
CONCLUSION
The presented case of a patient with a rare dis-
ease (RP) is interesting for practitioners who are un-
familiar with this pathology, and, as a rule, making a 
diagnosis presents significant difficulties. The lack of 
clinical criteria, specific histological and blood count 
changes, as well as the long time interval between re-
lapses, complicates the diagnosis and is a prerequisite 
for deformities in the area of the affected cartilage. In 
our case, it took 7 years from the first episode of the 
disease to the correct diagnosis.
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